0.09Open0.09Pre Close0 Volume22 Open Interest71.00Strike Price0.00Turnover3687.61%IV9.08%PremiumNov 29, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type-0.0473Delta0.0219Gamma866.56Leverage Ratio-237.6717Theta0.0000Rho-40.98Eff Leverage0.0001Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet